Albireo Pharma Inc Ano de IPO
Qual é o Ano de IPO de Albireo Pharma Inc?
O Ano de IPO de Albireo Pharma Inc é 2016
Qual é a definição de Ano de IPO?
A oferta pública inicia (OPI)l é um tipo de oferta pública em que as ações de uma empresa geralmente são vendidas a investidores institucionais que, por sua vez, vendem para o público em geral, em uma bolsa de valores, pela primeira vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Ano de IPO de empresas na Setor Health Care em NASDAQ em comparação com Albireo Pharma Inc
O que Albireo Pharma Inc faz?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Empresas com ano de ipo semelhantes a Albireo Pharma Inc
- The Toronto-Dominion Bank PFD SER 9 3.7% tem Ano de IPO de 2015
- Fura Gems tem Ano de IPO de 2015
- Hostess Brands tem Ano de IPO de 2015
- Nabriva Therapeutics Plc tem Ano de IPO de 2015
- REF tem Ano de IPO de 2015
- H-Source tem Ano de IPO de 2015
- Albireo Pharma Inc tem Ano de IPO de 2016
- American Pacific Borates tem Ano de IPO de 2017
- Razer tem Ano de IPO de 2017
- DEAG Deutsche Entertainment Aktiengesellschaft tem Ano de IPO de 2017
- Hamilton Beach Brands Co tem Ano de IPO de 2017
- Artelo Biosciences tem Ano de IPO de 2017
- VARTA AG tem Ano de IPO de 2017